GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Omni Bio Pharmaceutical Inc (GREY:OMBP) » Definitions » Cash Flow from Financing

Omni Bio Pharmaceutical (Omni Bio Pharmaceutical) Cash Flow from Financing : $2.00 Mil (TTM As of Dec. 2014)


View and export this data going back to 2007. Start your Free Trial

What is Omni Bio Pharmaceutical Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Dec. 2014, Omni Bio Pharmaceutical paid $0.00 Mil more to buy back shares than it received from issuing new shares. It received $0.50 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.00 Mil on other financial activities. In all, Omni Bio Pharmaceutical earned $0.50 Mil on financial activities for the three months ended in Dec. 2014.


Omni Bio Pharmaceutical Cash Flow from Financing Historical Data

The historical data trend for Omni Bio Pharmaceutical's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Omni Bio Pharmaceutical Cash Flow from Financing Chart

Omni Bio Pharmaceutical Annual Data
Trend Dec06 Dec07 Dec08 Mar09 Mar10 Mar11 Mar12 Mar13 Mar14
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only 1.79 0.22 3.44 1.45 1.36

Omni Bio Pharmaceutical Quarterly Data
Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 1.00 0.50 0.50

Omni Bio Pharmaceutical Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Omni Bio Pharmaceutical's Cash from Financing for the fiscal year that ended in Mar. 2014 is calculated as:

Omni Bio Pharmaceutical's Cash from Financing for the quarter that ended in Dec. 2014 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2014 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Omni Bio Pharmaceutical  (GREY:OMBP) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Omni Bio Pharmaceutical's issuance of stock for the three months ended in Dec. 2014 was $0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Omni Bio Pharmaceutical's repurchase of stock for the three months ended in Dec. 2014 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Omni Bio Pharmaceutical's net issuance of debt for the three months ended in Dec. 2014 was $0.50 Mil. Omni Bio Pharmaceutical received $0.50 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Omni Bio Pharmaceutical's net issuance of preferred for the three months ended in Dec. 2014 was $0.00 Mil. Omni Bio Pharmaceutical paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Omni Bio Pharmaceutical's cash flow for dividends for the three months ended in Dec. 2014 was $0.00 Mil. Omni Bio Pharmaceutical received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Omni Bio Pharmaceutical's other financing for the three months ended in Dec. 2014 was $0.00 Mil. Omni Bio Pharmaceutical received $0.00 Mil on other financial activities.


Omni Bio Pharmaceutical Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Omni Bio Pharmaceutical's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Omni Bio Pharmaceutical (Omni Bio Pharmaceutical) Business Description

Traded in Other Exchanges
N/A
Address
5350 South Roslyn, Suite 430, Greenwood Village, CO, USA, 80111
Omni Bio Pharmaceutical Inc is a US-based biopharmaceutical company, which is engaged in the exploration of new methods of use of alpha-1 antitrypsin (AAT). It offers AAT, a naturally occurring protein that is essential for normal liver and lung function and has been purified from human blood to treat patients suffering from emphysema due to AAT-deficiency. Further, it focuses on the research and development efforts of advancing its first recombinant molecule, AAT and an Fc component of immunoglobulin (AAT-Fc 2) into clinical trials. Geographically these activities are functioned through the region of US.

Omni Bio Pharmaceutical (Omni Bio Pharmaceutical) Headlines

No Headlines